(Q84444255)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20563900%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

title

Biologicals in osteoporosis: teriparatide and parathyroid hormone in women and men (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20563900%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

author name string

Jean-Pierre Devogelaer

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20563900%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Yves Boutsen

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20563900%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Daniel H Manicourt

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20563900%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

publication date

1 September 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20563900%20AND%20SRC:MED&resulttype=core&format=json

Current osteoporosis reports

6 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20563900%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20563900%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20563900%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

page(s)

154-161

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20563900%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s11914-010-0024-1

6 February 2020

exact match

0 references

cites work

Treatment of osteoporosis with human parathyroid peptide and observations on effect of sodium fluoride

1 reference

12 December 2020

Intermittent PTH(1-34) does not increase union rates in open rat femoral fractures and exhibits attenuated anabolic effects compared to closed fractures.

1 reference

12 December 2020

A novel human parathyroid hormone (1-34) analog for the treatment of osteoporosis

1 reference

12 December 2020

Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate

1 reference

12 December 2020

Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis

1 reference

12 December 2020

Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent.

1 reference

12 December 2020

Glucocorticoid-induced osteoporosis: mechanisms and therapeutic approach

1 reference

12 December 2020

Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment

1 reference

12 December 2020

Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal

1 reference

12 December 2020

The anabolic effect of human PTH (1-34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate--is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system?

1 reference

12 December 2020

Effect of raloxifene after recombinant teriparatide [hPTH(1-34)] treatment in postmenopausal women with osteoporosis

1 reference

12 December 2020

Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy

1 reference

12 December 2020

Impact of bisphosphonate wash-out prior to teriparatide therapy in clinical practice.

1 reference

12 December 2020

Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS).

1 reference

12 December 2020

Randomized trial of once-weekly parathyroid hormone (1-84) on bone mineral density and remodeling

1 reference

12 December 2020

Effect of transdermal teriparatide administration on bone mineral density in postmenopausal women

1 reference

12 December 2020

Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis

1 reference

12 December 2020

Effects of teriparatide retreatment in osteoporotic men and women

1 reference

12 December 2020

Vertebral fracture risk is reduced in women who lose femoral neck BMD with teriparatide treatment

1 reference

12 December 2020

Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers.

1 reference

12 December 2020

Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk

1 reference

12 December 2020

hPTH 1-34 treatment of osteoporosis with added hormone replacement therapy: biochemical, kinetic and histological responses

1 reference

12 December 2020

Daily and cyclic parathyroid hormone in women receiving alendronate

1 reference

12 December 2020

Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures

1 reference

12 December 2020

The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis.

1 reference

12 December 2020

Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial

1 reference

12 December 2020

Loss of cancellous bone mass and connectivity in ovariectomized rats can be restored by combined treatment with parathyroid hormone and estradiol

1 reference

12 December 2020

Parathyroid hormone(1-84) treatment of postmenopausal women with low bone mass receiving hormone replacement therapy

1 reference

12 December 2020

Consensus development conference: prophylaxis and treatment of osteoporosis

1 reference

12 December 2020

Effects of PTH and alendronate on type I collagen isomerization in postmenopausal women with osteoporosis: the PaTH study

1 reference

12 December 2020

One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis

1 reference

12 December 2020

Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1-34) and 1,25-dihydroxyvitamin D

1 reference

12 December 2020

Retreatment with teriparatide one year after the first teriparatide course in patients on continued long-term alendronate

1 reference

12 December 2020

Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis

1 reference

12 December 2020

Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis

1 reference

12 December 2020

Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate

1 reference

12 December 2020

Efficacy and Safety of Human Parathyroid Hormone-(1–84) in Increasing Bone Mineral Density in Postmenopausal Osteoporosis

1 reference

12 December 2020

Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial

1 reference

12 December 2020

Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial

1 reference

12 December 2020

Parathyroid hormone (PTH)-related protein(1-36) is equipotent to PTH(1-34) in humans

1 reference

12 December 2020

Reduced risk of back pain following teriparatide treatment: a meta-analysis

1 reference

12 December 2020

Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate

1 reference

12 December 2020

An orally active calcium-sensing receptor antagonist that transiently increases plasma concentrations of PTH and stimulates bone formation

1 reference

12 December 2020

The Effects of Parathyroid Hormone, Alendronate, or Both in Men with Osteoporosis

1 reference

12 December 2020

Demonstrated solid-state stability of parathyroid hormone PTH(1-34) coated on a novel transdermal microprojection delivery system

1 reference

12 December 2020

Bone formation markers in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.

1 reference

12 December 2020

Anabolic effect of low doses of a fragment of human parathyroid hormone on the skeleton in postmenopausal osteoporosis

1 reference

12 December 2020

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

1 reference

12 December 2020

Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs

1 reference

12 December 2020

Teriparatide or alendronate in glucocorticoid-induced osteoporosis

1 reference

12 December 2020

The effect of prior bisphosphonate exposure on the treatment response to teriparatide in clinical practice

1 reference

12 December 2020

Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial.

1 reference

12 December 2020

Ten years' experience with alendronate for osteoporosis in postmenopausal women

1 reference

12 December 2020

Effect of prior and ongoing raloxifene therapy on response to PTH and maintenance of BMD after PTH therapy

1 reference

12 December 2020

Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial

1 reference

12 December 2020

Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose

1 reference

12 December 2020

Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy.

1 reference

12 December 2020

Cancellous and cortical bone architecture and turnover at the iliac crest of postmenopausal osteoporotic women treated with parathyroid hormone 1-84

1 reference

12 December 2020

Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis

1 reference

12 December 2020

Parathyroid hormone-related protein for the treatment of postmenopausal osteoporosis: defining the maximal tolerable dose

1 reference

12 December 2020